Phaxiam
PHAXIAM Therapeutics is a biopharmaceutical company specializing in innovative bacteriophage-based therapies to combat resistant bacterial infections. Formed from the merger of ERYTECH and PHERECYDES in June 2023, the company aims to become a global leader in phage therapy, targeting critical infections such as those caused by Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. PHAXIAM is listed on Euronext Paris and the Nasdaq, and is involved in clinical development, strategic collaborations, and advancing treatments for severe resistance infections.
Industries
Nr. of Employees
medium (51-250)
Phaxiam
60 Avenue Rockefeller, 69008 Lyon, France
Patents
Pharmaceutical composition comprising erythrocytes encapsulating a PLP-dependent enzyme and, a non-phosphate PLP precursor
US-11458170-B2
View DetailsArginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
US-11273210-B2
View Details
Pharmaceutical composition comprising erythrocytes encapsulating a PLP-dependent enzyme and, a non-phosphate PLP precursor
US-11458170-B2
View DetailsArginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
US-11273210-B2
View DetailsProducts
In vitro phagogram diagnostic assay
An in vitro diagnostic assay for assessing bacteriophage susceptibility of bacterial clinical isolates to guide individualized phage therapy selection.
Portfolio of clinical-grade phage candidates
A pipeline of bacteriophage therapeutic candidates targeting major hospital-acquired pathogens including Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
In vitro phagogram diagnostic assay
An in vitro diagnostic assay for assessing bacteriophage susceptibility of bacterial clinical isolates to guide individualized phage therapy selection.
Portfolio of clinical-grade phage candidates
A pipeline of bacteriophage therapeutic candidates targeting major hospital-acquired pathogens including Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Services
Provision of bacteriophage-based treatments to eligible patients under compassionate or early-access regulatory frameworks and collection of outcome data.
Design and operational support for multicenter clinical trials and investigator-sponsored studies, including supply of clinical-grade phage material and scientific collaboration.
Partnerships to develop and deliver individualized GMP-manufactured bacteriophage therapies and to accelerate clinical and manufacturing capabilities.
Preparation and digital distribution of investor materials including financial reports, investor presentations, regulatory registration documents, press releases and subscription alerts for stakeholders.
Provision of bacteriophage-based treatments to eligible patients under compassionate or early-access regulatory frameworks and collection of outcome data.
Design and operational support for multicenter clinical trials and investigator-sponsored studies, including supply of clinical-grade phage material and scientific collaboration.
Partnerships to develop and deliver individualized GMP-manufactured bacteriophage therapies and to accelerate clinical and manufacturing capabilities.
Preparation and digital distribution of investor materials including financial reports, investor presentations, regulatory registration documents, press releases and subscription alerts for stakeholders.
Expertise Areas
- Phage therapy development
- Clinical trial management (Phase I/II)
- GMP biologics manufacturing
- Regulatory affairs (IND/CTA interactions with agencies)
Key Technologies
- Bacteriophage therapeutics
- GMP bioproduction
- In vitro diagnostic assays (phagogram)
- Phage susceptibility testing
News & Updates
Trading in PHAXIAM shares will remain suspended until the completion of the delisting procedure, following a request made to Euronext.
The Lyon Commercial Court has pronounced the judicial liquidation of PHAXIAM on June 11, 2025.
PHAXIAM Therapeutics announced the success of its capital increase with a retention of the preferential subscription right, raising approximately €7.8 million.
Trading in PHAXIAM shares will remain suspended until the completion of the delisting procedure, following a request made to Euronext.
The Lyon Commercial Court has pronounced the judicial liquidation of PHAXIAM on June 11, 2025.
PHAXIAM Therapeutics announced the success of its capital increase with a retention of the preferential subscription right, raising approximately €7.8 million.